PureHeart Medical OÜ

Active Registry code 17022164 OÜ Tallinn Registered 4 Jul 2024
Compare

PureHeart Medical OÜ is a OÜ based in Tallinn, registry code 17022164, status: active. Main activity: Research and experimental development on natural sciences and engineering. Its annual report for 2025 shows revenue of €5 164 and 0 employees.

Turnover
—
State taxes
1 722 €
↑ 137.8% vs Q2 2026
Labour taxes
1 722 €
↑ 121.3% vs Q2 2026
Employees
—

Q3 2026 · data from the Tax and Customs Board (EMTA)

Position in the industry Scientific research and development · EMTAK 72

  • Revenue · 2025 5 164 €
    industry median 0 € · companies in the industry: 1 073
  • Net profit margin · 2025 21.5 %
    industry median 13.5 % · companies in the industry: 597

Taxes and turnover

Q3 2024 – Q3 2026
Turnover, € Q4 2025: 4 149 € · industry median 13 976 € · above 29% of the industry
05 00010 00015 00020 000Q3 2024 Company: 0 € Industry median: 11 985 €Q3·24Q4 2024 Company: 0 € Industry median: 16 752 €Q4·24Q1 2025 Company: 0 € Industry median: 15 203 €Q1·25Q2 2025 Company: 0 € Industry median: 14 420 €Q2·25Q3 2025 Company: 0 € Industry median: 13 763 €Q3·25Q4 2025 Company: 4 149 € Industry median: 13 976 €Q4·25Q2 2026 Company: — Industry median: 14 545 €Q2·26Q3 2026 Company: — Industry median: 14 442 €Q3·2605 00010 00015 00020 000Q3 2024 Company: 0 € Industry median: 11 985 €Q4 2024 Company: 0 € Industry median: 16 752 €Q4·24Q1 2025 Company: 0 € Industry median: 15 203 €Q2 2025 Company: 0 € Industry median: 14 420 €Q2·25Q3 2025 Company: 0 € Industry median: 13 763 €Q4 2025 Company: 4 149 € Industry median: 13 976 €Q4·25Q2 2026 Company: — Industry median: 14 545 €Q3 2026 Company: — Industry median: 14 442 €Q3·26
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

State taxes, € Q3 2026: 1 722 € · +137.8% vs Q2 2026
05001 0001 5002 0002 500Q3 2024 Company: —Q3·24Q4 2024 Company: —Q4·24Q1 2025 Company: —Q1·25Q2 2025 Company: —Q2·25Q3 2025 Company: —Q3·25Q4 2025 Company: 2 184 €Q4·25Q2 2026 Company: 724 €Q2·26Q3 2026 Company: 1 722 €Q3·2605001 0001 5002 0002 500Q3 2024 Company: —Q4 2024 Company: —Q4·24Q1 2025 Company: —Q2 2025 Company: —Q2·25Q3 2025 Company: —Q4 2025 Company: 2 184 €Q4·25Q2 2026 Company: 724 €Q3 2026 Company: 1 722 €Q3·26
Figures by quarter
Quarter Turnover, € State taxes, € Labour taxes, € Employees
Q3 2026 — 1 722 1 722 —
Q2 2026 — 724 778 —
Q4 2025 4 149 2 184 1 278 —
Q3 2025 — — — —
Q2 2025 — — — —
Q1 2025 — — — —
Q4 2024 — — — —
Q3 2024 — — — —

Financials by year

2024 – 2025
Revenue, € 2025: 5 164 € · industry median 0 € · above 65% of the industry
02 0004 0006 0002024 Company: 0 € Industry median: 0 €20242025 Company: 5 164 € Industry median: 0 €202502 0004 0006 0002024 Company: 0 € Industry median: 0 €2025 Company: 5 164 € Industry median: 0 €2025
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit, € 2025: 1 108 € · +22 260.0% vs 2024 · industry median 0 € · above 65% of the industry
-25002505007501 0001 2502024 Company: -5 € Industry median: 0 €20242025 Company: 1 108 € Industry median: 0 €2025-25002505007501 0001 2502024 Company: -5 € Industry median: 0 €2025 Company: 1 108 € Industry median: 0 €2025
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit margin, % 2025: 21.5 % · industry median 13.5 % · above 54% of the industry
05101520252024 Company: — Industry median: 15.8 %20242025 Company: 21.5 % Industry median: 13.5 %202505101520252024 Company: — Industry median: 15.8 %2025 Company: 21.5 % Industry median: 13.5 %2025
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Assets, € 2025: 1 109 € · −55.7% vs 2024
01 0002 0003 0002024 Company: 2 505 €20242025 Company: 1 109 €202501 0002 0003 0002024 Company: 2 505 €2025 Company: 1 109 €2025
Equity, € 2025: 1 109 € · −55.6% vs 2024
05001 0001 5002 0002 5002024 Company: 2 495 €20242025 Company: 1 109 €202505001 0001 5002 0002 5002024 Company: 2 495 €2025 Company: 1 109 €2025
Employees 2025: 0 · industry median 1 · above 2% of the industry
0.00.20.40.60.81.02024 Company: 0 Industry median: 120242025 Company: 0 Industry median: 120250.00.20.40.60.81.02024 Company: 0 Industry median: 12025 Company: 0 Industry median: 12025
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Financials by year
Year Revenue, € Net profit, € Labour costs, € Assets, € Equity, € Employees
2025 5 164 1 108 2 929 1 109 1 109 0
2024 0 -5 0 2 505 2 495 0

Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.

Financial ratios for 2025

Net profit margin
21.5 %
Net profit / revenue
Return on equity (ROE)
99.9 %
Net profit / equity
Return on assets (ROA)
99.9 %
Net profit / assets
Equity ratio
100.0 %
Equity / assets
Debt ratio
0.0 %
Liabilities / assets

Annual reports

PDFs from e-Äriregister
Annual reports
Year Period Filed Report Documents
2025 1 Jan 2025 – 31 Dec 2025 30 Jun 2026 Company’s own e-Äriregister
2024 4 Jul 2024 – 31 Dec 2024 30 Jun 2025 Company’s own e-Äriregister

Board

Right of representation

Any member of the management board may represent the private limited company in all transactions.

Owners

Beneficial owners

Founders and other persons

Activities (EMTAK)

  • 72101Research and experimental development on natural sciences and engineering Main

Rulings 2

All rulings (PDF)
Rulings
Number, date Title Deadline State Document
Ä 50259025 / 2
4 Jun 2026
 Amendment entry In force
4 Jun 2026
 PDF
Ä 50259025
4 Jul 2024
 First entry In force
4 Jul 2024
 PDF

Sources: e-Äriregister and EMTA. Data updated 1 Nov 2026. Open at the source ↗ · Report an error in the data